Disease-modifying drugs for Alzheimer disease: implications for people in Canada

No disease-modifying medications for the treatment of Alzheimer disease have been approved in Canada. Lecanemab was the first disease-modifying medication for Alzheimer disease to be granted full approval by the US Food and Drug Administration, and a second such medication -- donanemab -- is under r...

Full description

Saved in:

Bibliographic Details
Published in:	Canadian Medical Association journal (CMAJ) Vol. 195; no. 42; pp. E1446 - E1448
Main Authors:	Watt, Jennifer A, Isaranuwatchai, Wanrudee, Grossman, Linda, Straus, Sharon E
Format:	Journal Article
Language:	English
Published:	Ottawa CMA Impact Inc 30-10-2023 CMA Impact, Inc
Subjects:	Alzheimer's disease Biomarkers Cerebrospinal fluid Cognitive ability Dementia Demographic aspects Development and progression Drug therapy Drugs FDA approval Health sciences Hypotheses Medical imaging Medical research Monoclonal antibodies Neuroimaging Patients Surveillance Canada United States > US
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	No disease-modifying medications for the treatment of Alzheimer disease have been approved in Canada. Lecanemab was the first disease-modifying medication for Alzheimer disease to be granted full approval by the US Food and Drug Administration, and a second such medication -- donanemab -- is under review by the agency; lecanemab is under review by Health Canada. If disease-modifying medications for Alzheimer disease are approved by Health Canada, substantial planning at the health system level is needed to support their implementation, because of high medication costs, and a clear need for postmarketing surveillance, given limited certainty of effect from existing trial data.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0820-3946 1488-2329
DOI:	10.1503/cmaj.230595